Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark Office. This patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the Company’s investigational new drug product. The treatment approach involves detecting the TT genotype of rs1042173 in the serotonin transporter gene and administering AD04. These treatment methods are tailored for individuals suffering from disorders such as opioid dependence, opioid abuse, alcohol dependence, and other related conditions.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals announce clinical study results from AD04-103 study
- Adial Pharmaceuticals Focuses on Strategic Growth Initiatives
- Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder
- Adial Pharmaceuticals files to sell 5.0M shares of common stock for holders
- Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital